RAF and MEK inhibition in melanoma cultures, we utilized RAF265 (a pan-RAF inhibitor), MEK162 (a MEK1/2 inhibitor) plus the MEK inhibitor trametinib. A panel of 22 patient-derived melanoma cultures was utilised; the IC50 for RAF265 and MEK162 are shown in Table 2. This was in comparison with the IC50 for trametinib (Further file 1: Table S1). Cells were treated with every single drug individually at concentrations ranging from 1 nM to 1000 nM and analyzed 3 days later. As shown in Table two, the IC50 for RAF265 ranged from 24 to 10000 nM, four to 2004 nM, and 62 to 2082 nM for WT, B-RAF mutant and N-RAS mutant cultures, respectively. The IC50 for MEK162 ranged from ten to 10000 nM, 1 to 150 nM, and four toThumar et al. Molecular Cancer 2014, 13:45 http://www.molecular-cancer/content/13/1/Page 4 ofFigure 1 Correlation between N-RAS mutation status and survival probability in melanoma sufferers. Kaplan-Meier survival curves demonstrating the general survival from time of diagnosis of stage IV disease. Panel A shows survival curves for all three patient groups, whereas panel B shows the patients with N-RAS mutations in comparison to B-RAF and WT combined. Individuals with N-RAS mutations had a trend towards shorter median survival when compared to the non N-RAS WT counterparts (p = 0.12).13 nM for WT, B-RAF mutant and N-RAS mutant melanoma cultures, respectively. The sensitivity to RAF265 in wild kind (2 out of five) and N-RAS (2 out of 7) melanoma cultures was low. Two wild kind cultures (YUROB and YUSOC) are sensitive to both RAF265 and MEK162. Six of ten B-RAF mutant cultures were sensitive to RAF265, and seven out of ten have been sensitive to MEK162. In N-RAS mutant melanomacultures, two out of 7 have been sensitive to RAF265 and, strikingly, all have been sensitive to MEK162. Of your 7 N-RAS mutant cultures, 5 were sensitive to trametinib.Indacaterol YUFIC and YUTICA had been extra resistant.Molecular effects of MEKDue for the striking sensitivity patterns of MEK162, we performed more studies to confirm target down-Table 2 Patient-derived melanoma cultures with their B-RAF/N-RAS mutational status and sensitivity to RAF265 and MEKName with the culture Wild typeB-RAF /N-RAS YUHOIN YUROB YUROL YUSOC YUVON B-RAF mutants YUCOT YUGEN YUKOLI YUKSI YUMAC YURIF YUSAC YUSIT YUSUBA YUZEAL N-RAS mutants YUCHER YUDOSO YUFIC YUGANK YUGASP YUKIM YUTICA Mutation WT WT WT WT WT V600E (GAG/GAG) V600E (GAG/GAG) V600E/WT (GAG/GTG) V600K (AAG/AAG) V600K (AAG/AAG) V600K (AAG/AAG) V600E (GAG/GAG) V600K/WT (AAG/GTG) V600E (GAG/GAG) V600R (AGG/AGG) Q61R (CGA/CGA) Q61K/WT (AAA/CAA) Q61R/WT (CGA/CAA) Q61K (AAA/AAA) Q61L (CTA/CTA) Q61R (AGA/AGA) Q61R/WT (CGA/CAA) RAF265 IC50s [nM] 1000 25 1000 72 1000 35 5 18 1000 208 412 1000 188 660 124 70 62 351 1000 1000 559 371 MEK162 IC50s [nM] 1000 10 1000 36 1000 1 108 27 150 8 45 148 25 50 33 6 9 5 five 10 8Thumar et al.Topiramate Molecular Cancer 2014, 13:45 http://www.PMID:23829314 molecular-cancer/content/13/1/Page five ofregulation inside the sensitive and resistant cultures. ERK1/2 isoforms are the instant downstream substrates and finest studied effectors of dual specificity kinases MEK1/2. To assess the effect of MEK1/2 inhibition on ERK1/2 activation state (phosphorylation at T202/Y204 web pages), melanoma cultures were treated with MEK162 and compared with untreated controls. We chosen one particular sensitive and 1 resistant culture within the WT and B-RAF mutant categories. Seeing that all N-RAS mutant cultures had been sensitive to MEK162, we selected two sensitive cultures for these studies. WT (YUVON and YUROB), B-RAF mutant.
bet-bromodomain.com
BET Bromodomain Inhibitor
